JointHealth™ express July 30, 2013
Do you have polyarticular juvenile idiopathic arthritis or care for someone who does? We want your valuable input.
On July 15, Arthritis Consumer Experts (ACE) sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).
There is still time to get involved. The CDR continues to accept input on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of polyarticular juvenile idiopathic arthritis (JIA).
If you live with polyarticular JIA or care for someone with the disease, please send us your input. Please provide your input by Monday, August 5, 2013, so that we may submit a report by the August 12 deadline.
Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview.
Do you have polyarticular juvenile idiopathic arthritis or care for someone who does? We want your valuable input.
On July 15, Arthritis Consumer Experts (ACE) sent out a JointHealth™ express announcing that we are gathering patient input to submit to the Common Drug Review (CDR).
There is still time to get involved. The CDR continues to accept input on the manufacturer’s submission for tocilizumab (Actemra®) for the treatment of polyarticular juvenile idiopathic arthritis (JIA).
If you live with polyarticular JIA or care for someone with the disease, please send us your input. Please provide your input by Monday, August 5, 2013, so that we may submit a report by the August 12 deadline.
Please contact us at info@jointhealth.org to provide your input or arrange for a phone interview.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.